A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 17, 2011, Pages 2613-2626

  Lock, Kevin ^a   Wilson, Koo ^b   Murphy, Daniel ^a   Riesco, Juan Antonio ^c  

^a Building 210A   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c San Pedro de Alcántara Hospital   (Spain)

Author keywords

COPD; Cost effectiveness; Smoking cessation

Indexed keywords

PLACEBO; VARENICLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FEMALE; FRANCE; GERMANY; GREECE; HEALTH CARE SYSTEM; HIDDEN MARKOV MODEL; HUMAN; ITALY; MALE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SMOKING CESSATION; SPAIN; TREATMENT RESPONSE; UNITED KINGDOM;

BENZAZEPINES; COST-BENEFIT ANALYSIS; EUROPE; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; NICOTINIC AGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING CESSATION;

EID: 81255142715     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.628935     Document Type: Article

References (51)

1. Feenstra TL, van Genugten ML, Hoogenveen RT, et al. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001;164:590-6
2. Stang P, Lydick E, Silberman C, et al.The prevalence of COPD: using smoking rates to estimate disease frequency in the general population. Chest 2000;117:354S-9S
3. WHO. Chronic respiratory diseases. Available from: http://www who int/ respiratory/copd/burden/en/index html,2011 Available from: http://www. who.int/respiratory/copd/burden/en/ index.html [Last accessed 10 August 2011]
4. GOLD. Executive Committee. Global Strategy for Diagnosis, Management, and Prevention of COPD. Available from: http://www goldcopd com/Guidelineitem asp?l1=2&l2=1&intId=2003,2009 Available from: http://www.goldcopd. com/Guidelineitem.asp? l1=2&l2=1&intId=2003 [Last accessed 29 March 2010]
5. Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009;64:863-8
6. Pena VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000;118:981-9
7. Alvarez-Sala J, Cimas E, Masa J, et al. Recommendations for the care of the patient with chronic obstructive pulmonary disease. Arch Bronconeumol 2001;37:269-78
8. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505
9. Scanlon PD, Connett JE, Waller LA,B et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161:381-90
10. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participant after 11 years. Am J Respir Crit Care Med 2002;166:675-9
11. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7
12. Coe JW, Vetelino MG, Bashore CG, et al. In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine. Bioorg Med Chem Lett 2005;15:2974-9
13. Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011;139:591-9
14. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005;26:223-33
15. Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004;7:153-67
16. Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:712-19
17. Healthcare Commission, Royal College of Physicians (UK). National Lung Cancer Audit. 2006
18. Eurostat Lifetables. Available from:http://epp eurostat ec europa eu/portal/ page/portal/eurostat/home,2010 Available from: http://epp.eurostat. ec.europa.eu/ portal/page/portal/eurostat/home [Last accessed 10 November 2010]
19. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-9
20. de Oca MM, Talamo C, Halbert RJ, et al. Frequency of self-reported COPD exacerbation and airflow obstruction in five Latin American cities: the Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) study. Chest 2009;136:71-8
21. Wetter DW, Cofta-Gunn L, Fouladi RT, et al. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 2004;39:1156-63
22. Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res 2002;4:95-100
23. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589-93
24. Paterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res 2000;9:521-7
25. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003;123:784-91
26. Rutten-van Molken MP, Oostenbrink JB, Miravitlles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007;8:123-35
27. Asukai Y, Valladares A, Camps C, et al. Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer 2010;10:26
28. Eurostat HICP Indices. Available from: http://epp eurostat ec europa eu/tgm/table do?tab=table&language= en&pcode= tsieb060&tableSelection= 1&footnotes=yes&labeling= labels&plugin=1,2010 Available from: http://epp.eurostat.ec.europa.eu/tgm/ table. do?tab=table&language=en& pcode=tsieb060&tableSelection =1&footnotes =yes&labeling=labels&plugin=1 [Last accessed 12 November 2010]
29. Detournay B, Pribil C, Fournier M, et al. The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France. Value Health 2004;7:168-74
30. Nowak D, Dietrich ES, Oberender P, et al. Cost-of-illness study for thetreatment of COPD in Germany. Pneumologie 2004;58:837-44
31. Maniadakis N, Tzanakis N, Fragoulakis V, et al. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Curr Med Res Opin 2006;22:1599-607
32. Lucioni C, Donner CF, De Benedetto F, et al. I costi della broncopneumopatia cronica ostruttiva: la fase prospecttica dello Studio ICE (Italian Costs for Exacerbations in COPD). 7th edition. 2005. p. 119-34
33. Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med 2003;97(Suppl C):S71-9
34. Weill A, Chinaud F, Vallier N, et al. Frequence et couts des trente affections de longue duree de la region Midi-Pyrenees, annee 2003 (Frequency and cost of the thirty long-term disorders in the Midi-Pyrenees region in 2003). Rev Med Ass Maladie 2005;36:273-87
35. Bolin K, Wilson K, Benhaddi H, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation-results from four European countries. Eur J Public Health 2009;19:650-4
36. Pagano E, Gregori D, Filippini C, et al. Impact of initial pattern of care on hospital costs in a cohort of incident lung cancer cases. J Eval Clin Pract 2010. [Epub ahead of print]
37. Parrott S, Godfrey C. Economics of smoking cessation. BMJ 2004;328:947-9
38. Gani R, Griffin J, Kelly S, Rutten-van MM. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Prim Care Respir J 2010;19:68-74
39. Joint Formulary Committee. British National Formulary. In: Joint Formulary Committee, editor. 59th edition. British Medical Association and Royal Pharmaceutical Society of Great Britain; London: 2010
40. Curtis L. Unit Costs of Health and Social Care 2009. Personal Social Services Research Unit; Canterbury, Kent: 2010
41. Eurostat PPP Indices. Available from: http://appsso eurostat ec europa eu/nui/show do?dataset=prc-ppp-ind&lang=en,2011 Available from: http://appsso.eurostat.ec. europa.eu/nui/show.do? dataset=prc-ppp-ind&lang= en [Last accessed 28 January 2011]
42. Maniadakis N, Fragoulakis V, Pallis AG, et al. Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. Ann Oncol 2010;21:1462-7
43. Briggs AH, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford University Press; Oxford, UK: 2006
44. Vicente Ortun. 30,000 Euros por AVAC [30,000 Euros per QALY]. 2004
45. Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008;26:497-511
46. de Miguel DJ, Carrasco GP, Garcia CM, et al. Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis 2008;3:701-12
47. Consejo General de Colegios Oficiales de Farmaceuticos. Catalogo de Especialidades Farmaceuticas. Consejo General de Colegios Oficiales de Farmaceuticos. Available from: https:// botplusweb portalfarma com/botplus asp,2010 Available from: https:// botplusweb.portalfarma.com/botplus.asp [Last accessed 1 May 2010]
48. Oblikue Consulting. Base de Datos de Costes. Available from: http://www oblikue com/bddcostes/,2010 Available from: http://www.oblikue.com/bddcostes/ [Last accessed 1 May 2010]
49. Price Bulletin. Available from: http:// www gge gr/37/sub asp?4616,2011 Available from: http://www.gge.gr/37/ sub.asp?4616 [Last accessed 2 June 2011]
50. Federfarma. Available from: http://www federfarma it/,2011 Available from: http://www.federfarma.it/ [Last accessed 2 June 2011]
51. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 2010;65:711-18